Cargando…

NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer

The mechanism by which the transcription factors inhibit the miRNA expression in ovarian cancer chemoresistance is unclear. The present study investigated the mechanism underlying the transcriptional repression of miR-134 in chemoresistant serous epithelial ovarian cancer. The results demonstrate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Shuang, Ting, Wang, Min, Zhou, Yingying, Shi, Cong, Wang, Dandan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421894/
https://www.ncbi.nlm.nih.gov/pubmed/28206956
http://dx.doi.org/10.18632/oncotarget.15267
_version_ 1783234674437390336
author Shuang, Ting
Wang, Min
Zhou, Yingying
Shi, Cong
Wang, Dandan
author_facet Shuang, Ting
Wang, Min
Zhou, Yingying
Shi, Cong
Wang, Dandan
author_sort Shuang, Ting
collection PubMed
description The mechanism by which the transcription factors inhibit the miRNA expression in ovarian cancer chemoresistance is unclear. The present study investigated the mechanism underlying the transcriptional repression of miR-134 in chemoresistant serous epithelial ovarian cancer. The results demonstrate that NF-κB1, c-Rel, and ELK1 are involved as transcription factors in repressing miR-134 expression in paclitaxel-resistant ovarian cancer cells. Knockdown of these transcription factors led to increased miR-134 expression, resulting in increased apoptosis and inhibition of proliferation in SKOV3-TR30 cells. NF-κB1, c-Rel, and ELK1 mRNA expression was upregulated in chemoresistant specimens and negatively correlated with miR-134 expression. Kaplan–Meier analysis revealed that high nuclear expressions of NF-κB1, c-Rel, ELK1 were significantly associated with short survival in serous epithelial ovarian cancer patients. Finally, TAB1 was identified as a functional target of miR-134, and the expression of TAB1 was increased by the transcription factors of NF-κB1, c-Rel, and ELK1 via miR-134. Taken together, these results provide an insight into the mechanism of repressed miR-134 expression in chemoresistance of serous epithelial ovarian cancer.
format Online
Article
Text
id pubmed-5421894
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-54218942017-05-10 NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer Shuang, Ting Wang, Min Zhou, Yingying Shi, Cong Wang, Dandan Oncotarget Research Paper The mechanism by which the transcription factors inhibit the miRNA expression in ovarian cancer chemoresistance is unclear. The present study investigated the mechanism underlying the transcriptional repression of miR-134 in chemoresistant serous epithelial ovarian cancer. The results demonstrate that NF-κB1, c-Rel, and ELK1 are involved as transcription factors in repressing miR-134 expression in paclitaxel-resistant ovarian cancer cells. Knockdown of these transcription factors led to increased miR-134 expression, resulting in increased apoptosis and inhibition of proliferation in SKOV3-TR30 cells. NF-κB1, c-Rel, and ELK1 mRNA expression was upregulated in chemoresistant specimens and negatively correlated with miR-134 expression. Kaplan–Meier analysis revealed that high nuclear expressions of NF-κB1, c-Rel, ELK1 were significantly associated with short survival in serous epithelial ovarian cancer patients. Finally, TAB1 was identified as a functional target of miR-134, and the expression of TAB1 was increased by the transcription factors of NF-κB1, c-Rel, and ELK1 via miR-134. Taken together, these results provide an insight into the mechanism of repressed miR-134 expression in chemoresistance of serous epithelial ovarian cancer. Impact Journals LLC 2017-02-11 /pmc/articles/PMC5421894/ /pubmed/28206956 http://dx.doi.org/10.18632/oncotarget.15267 Text en Copyright: © 2017 Shuang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Shuang, Ting
Wang, Min
Zhou, Yingying
Shi, Cong
Wang, Dandan
NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer
title NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer
title_full NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer
title_fullStr NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer
title_full_unstemmed NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer
title_short NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer
title_sort nf-κb1, c-rel, and elk1 inhibit mir-134 expression leading to tab1 upregulation in paclitaxel-resistant human ovarian cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421894/
https://www.ncbi.nlm.nih.gov/pubmed/28206956
http://dx.doi.org/10.18632/oncotarget.15267
work_keys_str_mv AT shuangting nfkb1crelandelk1inhibitmir134expressionleadingtotab1upregulationinpaclitaxelresistanthumanovariancancer
AT wangmin nfkb1crelandelk1inhibitmir134expressionleadingtotab1upregulationinpaclitaxelresistanthumanovariancancer
AT zhouyingying nfkb1crelandelk1inhibitmir134expressionleadingtotab1upregulationinpaclitaxelresistanthumanovariancancer
AT shicong nfkb1crelandelk1inhibitmir134expressionleadingtotab1upregulationinpaclitaxelresistanthumanovariancancer
AT wangdandan nfkb1crelandelk1inhibitmir134expressionleadingtotab1upregulationinpaclitaxelresistanthumanovariancancer